Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Keybanc Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $6

Author: Benzinga Newsdesk | December 05, 2023 07:03am

Keybanc analyst Scott Schoenhaus initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Overweight rating and announces Price Target of $6.

Posted In: ABCL